Chemotherapy-induced cardiotoxicity refers to damage or weakening of the heart caused by certain cancer treatments. While chemotherapy and other cancer therapies play a vital role in treating cancer, some medications can affect the heart muscle, heart valves, blood pressure, or heart rhythm in certain patients. Early detection and monitoring of heart function are extremely important because many cardiac complications can be identified and managed before permanent damage occurs.
Patients receiving chemotherapy may sometimes develop symptoms such as breathlessness, fatigue, swelling of the legs, palpitations, chest discomfort, dizziness, or reduced exercise tolerance. However, in many cases, early heart damage may not cause noticeable symptoms initially. This is why regular cardiac evaluation during and after cancer treatment is very important, especially in patients receiving medications known to affect the heart.
Cardiotoxicity evaluation usually begins with baseline heart assessment before starting chemotherapy. This commonly includes ECG, echocardiography, blood pressure evaluation, and blood investigations. Advanced echocardiographic techniques such as Strain Echocardiography (Global Longitudinal Strain imaging) are especially useful because they can detect very early heart muscle dysfunction even before the routine heart pumping function becomes abnormal.
Patients receiving certain chemotherapy drugs, targeted therapies, immunotherapy, or radiation therapy may require periodic cardiac monitoring throughout treatment. Serial echocardiography and cardiac evaluations help assess whether the heart function is remaining stable or showing early signs of stress or weakening. Early identification allows timely adjustment of cancer therapy and initiation of protective heart medications when necessary.
In selected patients, advanced cardiac imaging and nuclear imaging techniques may also be used for detailed assessment of heart function. PET (Positron Emission Tomography) and SPECT (Single Photon Emission Computed Tomography) imaging can help evaluate blood flow to the heart muscle, detect inflammation, assess heart muscle viability, and identify early changes related to chemotherapy-induced cardiac injury. MUGA scan (Multigated Acquisition Scan), another nuclear imaging test, may also be used for accurate measurement of heart pumping function during chemotherapy follow-up.
Modern cardio-oncology care focuses on balancing effective cancer treatment while protecting long-term heart health. In selected patients, medications may be prescribed to support heart function and reduce the risk of chemotherapy-related cardiac damage. Careful coordination between oncologists and cardiologists helps optimize both cancer treatment outcomes and cardiovascular safety.
Chemotherapy-induced cardiotoxicity evaluation plays an important role in preventing long-term heart complications in cancer survivors. Early monitoring, advanced imaging techniques, regular follow-up, and timely intervention help preserve heart function and improve overall quality of life during and after cancer treatment.
ESC
